Rue Santos-Dumont
1
6041 GOSSELIES
Belgium
[email protected] +32 71 23 96 00 bioxodes.com

Bioxodes is a clinical stage company developing a first-in-class drug candidate, Ir-CPI, for the prevention of thrombosis and neuroinflammation in haemorrhagic stroke patients.

About

Related news

News

Learn more
Bioxodes-brain-image2

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients

    Press release

24.04.2025

Learn more

Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe

    Press release

05.03.2025

Learn more
bioxodes2

Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing

    Press release

12.02.2025